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Background: The role of estrogen receptor beta (ER-β) in breast cancer (BC) remains unclear. Some studies have
suggested that ER-β may oppose the actions of estrogen receptor alpha (ER-α), and clinical evidence has indicated
that the loss of ER-β expression is associated with a poor prognosis and resistance to endocrine therapy. The
objective of the present study was to determine the role of ER-β and the ER-α/ER-β ratio in predicting the response
to endocrine therapy and whether different regimens have any effect on ER-β expression levels.
Methods: Ninety postmenopausal patients with primary BC were recruited for a short-term double-blinded
randomized prospective controlled study. To determine tumor cell proliferation, we measured the expression of
Ki67 in tumor biopsy samples taken before and after 26 days of treatment with anastrozole 1 mg/day (N = 25),
tamoxifen 20 mg/day (N = 24) or placebo (N = 29) of 78 participants. The pre- and post-samples were placed in
tissue microarray blocks and submitted for immunohistochemical assay. Biomarker statuses (ER-β, ER-α and Ki67)
were obtained by comparing each immunohistochemical evaluation of the pre- and post-surgery samples using
the semi-quantitative Allred’s method. Statistical analyses were performed using an ANOVA and Spearman’s
correlation coefficient tests, with significance at p ≤ 0.05.
Results: The frequency of ER-β expression did not change after treatment (p = 0.33). There were no significant
changes in Ki67 levels in ER-β-negative cases (p = 0.45), but in the ER-β-positive cases, the anastrozole (p = 0.01) and
tamoxifen groups (p = 0.04) presented a significant reduction in post-treatment Ki67 scores. There was a weak but
positive correlation between the ER-α and ER-β expression levels. Only patients with an ER-α/ER-β expression ratio
between 1 and 1.5 demonstrated significant differences in Ki67 levels after treatment with anastrozole (p = 0.005)
and tamoxifen (p = 0.026).
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Conclusions: Our results provide additional data that indicate that the measurement of ER-β in BC patients may
help predict tamoxifen and anastrozole responsiveness in the neoadjuvant setting. These effects of hormonal
treatment appear to be dependent on the ratio of ER-α/ER-β expression.
Trial registration: Current Controlled Trials ISRCTN89801719
Keywords: Estrogen receptor beta, Breast cancer, Estrogen receptor, Aromatase inhibitors/Anastrozole, Tamoxifen,
Ki67, Neoadjuvant therapy, Tumor markersBackground
Breast cancer (BC) is the most frequently diagnosed
non-skin cancer among women worldwide [1-3]. The
survival rate at 5 years after diagnosis in the United
States has improved from 63% in the early 1960s to 89%
currently [3]. Adjuvant hormone therapy has helped
achieve this substantial reduction in mortality because
approximately 75% of human BCs express estrogen re-
ceptors (ERs) [4-6].
Estrogens play a central role in the development and
growth of both normal and malignant mammary tissues.
In addition, they mediate most of their action through
the alpha ER (ER-α) [7]. Pathological lesions associated
with increased risk of BC also present significantly more
cells expressing ERs [8]. The ER-α status of breast tu-
mors provides prognostic information and is the primary
target for endocrine therapy. Effective strategies to treat
ER-positive BC include endocrine agents that compete
with estrogen for binding to its receptor, such as select-
ive estrogen-receptor modulators (SERMs) and anties-
trogens or reducing the levels of circulating estrogens by
the administration of agents such as third-generation
aromatase inhibitors (AIs), which have been shown to be
more effective than tamoxifen in postmenopausal women
in neoadjuvant and adjuvant settings [9].
The discovery in 1996 [10] of a second ER subtype,
known as beta (ER-β), which presented different expres-
sion profiles in normal and malignant tissues, opened
the possibility that breast tumors might be even more
heterogeneous than originally thought. The role of ER-β
in BC initiation and development has not yet been
clearly established [11]. In vitro experiments have dem-
onstrated that ER-β inhibits the proliferation, migration
and invasion of BC cells [12-15] and the angiogenesis
and growth of tumor xenografts [16]. The potential clin-
ical use of ER-β in BC endocrine therapy has been inves-
tigated in retrospective studies, and ER-β positivity has
been associated with significantly better survival in pa-
tients with ER-α-negative, progesterone receptor (PgR)-
negative and triple-negative tumors treated with adjuvant
tamoxifen therapy. These types of tumors are widely be-
lieved to be hormone unresponsive [17].
Despite initial positive responses to tamoxifen therapy,
one-third of all patients will develop resistance, thoughtheir ER-α status may remain unchanged [18,19]. A
lower expression of ER-β is found in tamoxifen-resistant
tumors, and high levels of ER-β are occasionally associ-
ated with a better clinical outcome in ER-α-positive
breast tumors [11]. Several studies have suggested that
the expression of ER-β independently predicts a better
disease-free survival in patients treated with tamoxifen
[20]. However, some data have suggested that the posi-
tivity of ER-β is associated with low cellular differenti-
ation, which indicates that this receptor could be related
to worse overall survival [21].
Data from a number of studies comparing neoadjuvant
and adjuvant endocrine treatments are now available
[22]. The measurement of Ki67, a cell proliferation
marker, after neoadjuvant endocrine therapy can predict
the efficacy of these drugs and reflect the ability of endo-
crine treatment to suppress proliferation [23,24]. Indeed,
Ki67 levels after 2 weeks of treatment was significantly
correlated with relapse-free survival in the Arimidex,
Tamoxifen, Alone or in Combination trial [23,25]. How-
ever, while the expression of ER-α has been extensively
studied as a predictive marker of treatment response,
the role of ER-β remains controversial and has never
been examined in a neoadjuvant short-term trial.
In this context, the objective of the present study was
to determine the role of ER-β and the ER-α/ER-β expres-
sion ratio in predicting the response to BC endocrine
therapy with anastrozole and tamoxifen. We also focused
on whether these different regimens have any effect on
ER-α and ER-β expression levels. Hormone receptor pro-
teins were detected semi-quantitatively using immuno-
histochemistry, and we compared the expression levels of
Ki67, ER-β and ER-α before and after neoadjuvant short-
term treatment in postmenopausal women with invasive
carcinomas.
Methods
Study design, patients and treatment protocol
We designed a randomized, prospective, controlled,
double-blind study that included postmenopausal women
with invasive BCs.
The eligibility criteria for the study included histologi-
cally confirmed primary stage II to III invasive BC in
women who were postmenopausal, which was defined as
Eligibility criteria (postmenopausal, Stage II to III BC)
90 Patients
Placebo
N = 29
Anastrozole 1 mg/day
N = 25
Tamoxifen 20 mg/day
N = 24
Randomization
Surgery (after 26 days)
Tumor markers: ER-α, ER-β, Ki-67
Biopsy before
randomization
Tumor markers:
ER-α, ER-β, Ki-6712 protocol violations:•8 subjects did not take 
tablets correctly
•3 subjects did not proceed
to surgery in time
•1 hormone analysis
Figure 1 Trial schematic design.
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a follicle-stimulating hormone level within the postmen-
opausal range. The exclusion criteria were the presence
of endocrine disease, metastatic disease, inflammatory
BC (T4d), history of thromboembolism and any previous
treatment for BC (surgery, radio or chemotherapy). Pa-
tients who did not comply with the prescribed medica-
tion regimen or postponed surgery were also excluded
from the study. Patients who had previously taken hor-
mone replacement therapy were included if they had
stopped hormonal treatment at least 6 months prior to
trial randomization.
After written informed consent was obtained, 90 pa-
tients with invasive BCs were recruited into the study and
enrolled at Pérola Byington Hospital and Federal Univer-
sity of São Paulo Hospital, Sao Paulo, Brazil, between
October 2010 and May 2012. The first tumor sample was
obtained from each patient at the time of diagnosis by in-
cisional biopsy performed in an outpatient facility using
local anesthesia. A second tumor specimen was obtained
from each patient during definitive surgery under general
anesthesia. Both tumor samples were processed using the
same paraffin-embedding technique.
The patients underwent definitive surgical treatment
(modified radical mastectomy or conservative surgery
with axillary evaluation) following a mean period of
26 days (range of 24–30 days and median of 26 days)
after the incisional biopsy. There were 3 major protocol
violations. These were performed by patients who did
not take tablets correctly (N = 8), did not proceed to sur-
gery in time (N= 3) or were premenopausal according to a
hormone analysis (N = 1). These patients were not in-
cluded in any analyses. Seventy-eight patients with oper-
able BCs completed the study and were randomized to
receive 26 days of treatment with anastrozole (N = 25)
(1 mg/day), tamoxifen (N = 24) (20 mg/day) or placebo
(N = 29) (Figure 1). Randomization and allocation to trial
groups were carried out by a central computer system [26].
The study was approved by the Human Investigation
Committees of Federal University of São Paulo and
Pérola Byington Hospital under the process number
CEP 0894/10, Brazil, and conducted in accordance with
the Helsinki Declaration.
Histology and tissue microarray construction
All samples were fixed in 10% neutral-buffered formalin,
processed and embedded in paraffin. Respective paired
tumor blocks containing samples obtained from all pa-
tients prior to any of the interventions and during de-
finitive surgery were retrieved from the pathology files of
our institution.
Specimen pairs were cut into 4-μm sections, mounted
on lysine-coated slides, stained with hematoxylin and
eosin and examined to confirm the diagnosis ofcarcinoma. The same slides were used by one path-
ologist investigator (AFL) to determine the area of
interest (the most representative of the tumor) to be
included in the tissue microarray (TMA) marked on
the slide. Using a marking pen, the corresponding re-
gion was circled on the archival “donor” paraffin block.
Tumor TMA blocks were obtained by punching 2-nm
tissue cores from each donor paraffin block. The samples
were then arrayed onto a recipient blank block using a
manual tissue arrayer (Beecher Instruments, Sun Prairie,
WI, USA) [27]. Control tissues were included in each of
these paraffin blocks.
Immunohistochemistry assays
After construction, 3-μm tissue sections were cut and
transferred to silanized slides and then left to dry over-
night at 56°C. The next day, the slides were dewaxed in
xylene, rehydrated in graded alcohol solutions and
washed with water. Antigen retrieval was performed
using a pressure cooker (Eterna, Nigro, Sao Paulo,
Brazil) and 10 mM citrate buffer, pH 6.0. The samples
were quenched with 6% hydrogen peroxide and incu-
bated overnight at 4°C with primary monoclonal anti-
bodies for ER-α (clone SP1, Neomarkers), ER-β (clone
14C8, GeneTex) and Ki67 (clone MIB-1, DAKO). The
following day, the slides were rinsed with phosphate-
buffered saline (PBS) and incubated with the second-
ary antibody (biotinylated goat anti-mouse/rabbit
immunoglobulin) diluted 1:200 for 30 min at 37°C.
The slides were rinsed again with PBS and incubated
with streptavidin-biotinylated-peroxidase complex (1:200,
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DakoCytomation, Carpinteria CA, USA) for 30 min at
37°C. The slides were developed with 0.06% diaminobenzene
as the chromogen with 0.06% hydrogen peroxide and
counterstained with Harris’ hematoxylin [27]. Positive
and negative control slides were included.
Biomarker scoring
The results of immunohistochemistry were assessed by 2
investigators (AFL and MM) in a blinded fashion, inde-
pendently examining the whole slide. In most cases
(kappa coefficient = 0.78), the estimations of the 2 inves-
tigators were identical, and discrepancies were resolved
by joint review of the slides. All slides were examined
and scored semi-quantitatively according to Allred’s cri-
teria using 2 parameters: the proportion of positive cells
and the staining intensity. These parameters were inde-
pendently recorded for each immunohistochemical reac-
tion. The distribution of the proportional fraction of
stained cells on each slide was scored using a scale from
0 to 5. The intensity of staining was scored from 0 to 3.
The sum of these 2 partial scores resulted in a final
score. Zero on this scale indicated that no cells were
stained, and scores ranging from 2 to 8 indicated differ-
ent levels of scoring. All cases with a final score equal to
or greater than 3 were considered positive [28,29].
Statistical analysis
The statistical analysis was conducted by an independent
statistician. The hormone therapy for each patient was
coded to maintain the blind assessment and avoid bias.
The analytical process used the IBM SPSS Statistics 19
software (IBM, USA).
Descriptive statistics were used to summarize the sample
characteristics at baseline (mean, standard deviation, mini-
mum, median and maximum). The number of valid obser-
vations was used to summarize the numeric variables, and
frequency and percentage were used to summarize the cat-
egorical variables. The groups were tested for homoscedas-
ticity, also known as homogeneity of variance.
The changes in the ER-β scores over time among the
groups (anastrozole, tamoxifen and placebo) were evalu-
ated with an ANOVA with repeated measures using rank
transformation.
The changes in the Ki67 scores over time and differ-
ences among groups (anastrozole, tamoxifen and pla-
cebo) were evaluated with an ANOVA with repeated
measures for the ER-β-positive and ER-β-negative cases.
To investigate whether a correlation between ER-α and
ER-β existed, we calculated the Spearman’s correlation
coefficient, and graphs of the expression level of each re-
ceptor were constructed.
The changes in the Ki67 scores over time and among
groups (anastrozole, tamoxifen and placebo) were evaluatedfor different ER-α/ER-β expression ratios with an ANOVA
with repeated measures using rank transformation.
The Bonferroni correction (a multiple-comparison
test) was used to adjust the p values for multiple test-
ing. All tests were performed with a significance level
of 0.05 (p ≤ 0.05).
Results
A total of 78 patients were included in our analyses. The
statistical analysis showed that there were no significant
differences in clinical characteristics between groups
(age, age at first menstrual period, age at menopause,
number of children, age at birth of first child or tumor
size; all p > 0.10); therefore the sample was considered
homogeneous. The mean age of the patients included in
the study was 65.7 years, with a range of 42–89 years
and median of 67 years. The mean age at menopause
was 48 years, with a range of 32–60 years and median of
50 years. The average tumor size was 3.9 cm, with a
range of 2.5–8.0 cm and median of 4.0 cm. The majority
of patients had stage II carcinoma.
Three tumor samples obtained at the time of diagnosis
and/or during definitive surgery had insufficient invasive
cancer in the biopsy when re-cut for the ER-β study,
resulting in a final number of 75 patients for the recep-
tor analysis. Examples of immunoreactivity for ER-β, ER-
α and Ki67 are shown in Figure 2. The mean pre- and
post-treatment Allred scores for ER-β are presented in
Table 1. The frequency of ER-β expression did not
change after treatment (p = 0.33).
The distribution of patients in each study group and
among randomized treatments as well as the number of
ER-α-positive cases are presented in Table 2.
There was not a significant change of Ki67 levels
during neoadjuvant treatment in ER-β-negative cases
(p = 0.45). In these patients, the mean pre- and post-
treatment Ki67 scores were 2.3 and 2.2 in the placebo
group, 4.2 and 3.5 in the anastrozole group and 4.6 and
3.4 in the tamoxifen group, respectively (Table 3). How-
ever, in the ER-β positive cases, the anastrozole group
(p = 0.01) and tamoxifen group (p = 0.04) presented a
significant reduction in post-treatment Ki67 Allred
scores compared with baseline. In these cases, the mean
pre- and post-treatment Ki67 scores were 3.6 and 4.0 in
the placebo group, 4.5 and 3.2 in the anastrozole group
and 3.8 and 2.9 in the tamoxifen group, respectively
(Table 3 and Figure 3).
Fifty-seven of 78 cases were positive for ER-α (Table 2).
The Spearman’s correlation coefficients indicated a
weak but positive correlation between ER-α and ER-β
(r = 0.21, p = 0.08 in pretreatment and r = 0.25, p = 0.03
in post-treatment). Eleven of 47 ER-β-positive cases were
negative for ER-α. Unfortunately, the number of cases
for each subdivision (groups and according to positive
Figure 2 Immunohistochemical staining pattern in BC samples for ER-β, ER-α and Ki67. A-E examples of ER-β expression: liver as negative
control (A), whole section positive control slide (B), Allred score 3 (C), Allred score 5 (D) and Allred score 8 (E). F-H examples of ER-α expression:
Allred score 0 (F), Allred score 6 (G) and Allred score 8 (H). I-L examples of Ki67 expression; Allred score 0 (I), Allred score 2 (J), Allred score 5 (K)
and Allred score 8 (L).
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tively small especially for the ER-β-negative and ER-α
-negative cases, which prevented a separate statistical
analysis of Ki67 variation after treatment in each group.
We calculated the ratio of the ER-α/ER-β pre-treatment
Allred scores and subdivided these patients in 3 groups:
ratio < 1 (patients with a much higher ER-β than ER-α
score), ratio between 1 and 1.5 (patients with similar
scores between the 2 receptors and a slightly higher ER-α
score) and ratio > 1.5 (patients with a much higher ER-αthan ER-β score). If the denominator (ER-β score) of the
fraction was zero, we considered as ratio > 1.5 (patients
with a much higher ER-α than ER-β score). The exception
was when the numerator (ER-α) was zero too. In this case
(ER-α = zero and ER-β = zero), we considered as ratio < 1.
Examples of pretreatment ER-α/ER-β ratios and post-
treatment Ki67 are shown in Figure 4.
After short-term treatment, there were no significant
changes in Ki67 levels in the ratio < 1 (p = 0.30) and ra-
tio > 1.5 (p = 0.41) cases. In patients with higher ER-β
Table 1 Changes of ER-β scores between treatment groups
A P T Total
Pre-treatment
Mean ± SD 3.21 ± 2.81 3.21 ± 2.63 4.17 ± 2.57 3.51 ± 2.67
Median (minimum–maximum) 3 (0–8) 4 (0–7) 5 (0–8) 4 (0–8)
Total (n) 24 28 23 75
Post-treatment
Mean ± SD 4 ± 2.31 2.93 ± 2.45 5 ± 2.04 3.91 ± 2.41
Median (minimum–maximum) 4 (0–7) 4 (0–7) 6 (0–8) 4 (0–8)
Total (n) 25 28 23 76
A: anastrozole group; P: placebo group; T: tamoxifen group; SD: standard deviation.
ANOVA with repeated measures using rank transformation: treatment (p = 0.3312) and group × treatment (p = 0.3052).
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treatment Ki67 scores were 4.0 and 4.8 in the placebo
group, 5.8 and 4.6 in the anastrozole group and 3.8 and
3.5 in the tamoxifen group, respectively. In patients with
much higher ER-α than ER-β scores (ratio > 1.5), the
mean pre- and post-treatment Ki67 scores were 2.7 and
2.6 in the placebo group, 4.0 and 3.5 in the anastrozole
group and 4.3 and 3.4 in the tamoxifen group, respectively.
However, the patients with an ER-α/ER-β score ratio be-
tween 1 and 1.5 demonstrated significant differences in
Ki67 levels after treatment. For the anastrozole (p = 0.005)
and tamoxifen (p = 0.026) groups, the Ki67 score was sig-
nificantly lower after treatment compared with the first bi-
opsy Ki67 score (Figure 5).
Discussion
The development of new treatments and the assessment
of biomarkers to improve BC patient outcomes require
very large randomized adjuvant clinical trials that may
extend over several years before the first results are
available. Neoadjuvant studies provide an opportunity to
integrate the molecular determinants of response and re-
sistance with the clinical response of primary BC to
medical therapy [23,30,31].
The optimum time to evaluate biomarkers for tumor
response (apoptosis and proliferation) is not defined.
Although cellular changes have been described in vitro
after 24 hours of drug exposure, Dowsett et al [23]Table 2 Distribution of patients in the study groups and amo
A (pre-treatment) P (pr
n ER-α-positive n
ER- β-negative 11 9 12
ER- β-positive 13 9 16
ER-α/ER-β ratio < 1 5 2 5
ER-α/ER-β ratio between 1 and 1.5 9 7 7
ER-α/ER-β ratio > 1.5 10 9 16
A: anastrozole group; P: placebo group; T: tamoxifen group.
ER-α-positive: number of patients in each group considered positive to ER-α (final Areported that after two weeks of neoadjuvant treatment of
primary breast cancer with anastrozole and tamoxifen, cel-
lular changes are similar to those observed after 12 weeks
of treatment. As other similar studies [23,25,28,30], the
classical dose of tamoxifen (20 mg/day) is enough to reach
steady state after 14 days of short-term treatment. The
period of 26 days was chosen because this is the average
time needed to complete routine preoperative testing in
our institutions, justifying the inclusion of ER-α-negative
patients and the use of placebo without ill consequences
to the ER-α-positive patients.
Although there is no consensus, the clinicopathologic
importance of ER-β expression in BC is emerging, in-
cluding its connection with factors usually associated
with a better clinical outcome [11,17,32,33]. Until now,
data about these favorable prognoses were based on pro-
tein studies in BC tissues and cellular experiments [34]
or retrospective studies that have assessed ER-β expres-
sion in relation with the clinical outcome associated with
endocrine therapy in BC [35]. In the present study, ER-β
expression did not change with exposure to any of the
tested drugs, but ER-β-positive postmenopausal patients
treated with anastrozole and tamoxifen presented a sig-
nificant reduction of Ki67 expression after neoadjuvant
short-term treatment.
Post-treatment ER-β expression did not vary signifi-
cantly between the 3 groups. This is similar to ER-α ex-
pression, which did not vary significantly, as reported inng randomized treatments
e-treatment) T (pre-treatment) Total
ER-α-positive n ER-α-positive n ER-α-positive
9 5 3 28 21
14 18 13 47 36
2 8 4 18 8
6 6 5 22 18
15 9 7 35 31
llred score equal to or greater than 3).
Table 3 Allred scores of Ki67 biomarker immunohistochemistry results in ER-β-negative and ER-β-positive cases
Ki67 Anastrozole (A) Placebo (P) Tamoxifen (T)
Pre-treatment Post-treatment Pre-treatment Post-treatment Pre-treatment Post-treatment
ER- β-negative
Mean ± SD 4.2 ± 1.9 3.5 ± 2.8 2.3 ± 1.4 2.2 ± 1.7 4.6 ± 1.9 3.4 ± 2.7
Median (minimum–maximum) 4 (2–8) 2 (0–8) 2 (0–4) 2 (0–5) 4 (2–7) 3 (0–7)
Total (n) 11 11 12 12 5 5
ER- β-positive
Mean ± SD 4.5 ± 2 3.2 ± 2.1* 3.6 ± 1.8 4 ± 1.6 3.8 ± 1.8 2.9 ± 2.1**
Median (minimum–maximum) 4 (0–7) 2 (0–7) 4 (0–6) 4 (2–6) 4 (0–6) 3 (0–7)
Total (n) 13 13 16 16 18 18
SD: standard deviation.
ER-β-negative: ANOVA with repeated measures: group (p = 0.071), treatment (p = 0.084) and group × treatment (p = 0.446).
ER-β-positive: ANOVA with repeated measures: group (p = 0.726), treatment (p = 0.036) and group × treatment (p = 0.032).
Bonferroni multiple comparison test for ER-β-positive analysis: group A (pre- × post-treatment: p = 0.014*), group P (pre- × post-treatment: p = 0.113) and group T
(pre- × post-treatment: p = 0.046**).
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Combined with Tamoxifen trial [25] and in more recent
studies [28]. Thus, post-treatment ER-β expression alone
does not appear to be an early predictor of response to
short-term anastrozole and tamoxifen therapies. In a
randomized trial of vorozole versus tamoxifen [36], there
was a decrease in ER-α expression with both drugs, and
this has also been found in a study comparing letrozole
and tamoxifen [24]. However, in stimulation assays,
Smollich et al [37] indicated that tamoxifen and fulvestrant
increased ER-α expression and left ER-β expression
unchanged, while AI up-regulated ER-β (anastrozole,
p = 0.029; letrozole, p = 0.048). These data indicate that
SERMs/antiestrogens and AI can exhibit opposing effects
on the ER expression of BC cells, which may contribute to
the therapeutic superiority of AI over antiestrogens. Inter-
estingly, it has been found that ER-β is significantly up-
regulated, whereas ER-α is down-regulated in tumors after
treatment of premenopausal women with BCs with adju-
vant letrozole in combination with gonadotropin-releasing
hormone (GnRH) analogues [38]. In addition, patients
treated with anastrozole but not with tamoxifen have a sig-
nificant reduction in PgR expression [25,28,29]. It is likelyKi
67
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Figure 3 Changes in Ki67 after short-term treatment of ER-β
-positive breast cancer.that the production of estrogen is consistently blocked and
that the expression PgR is significantly reduced by the ac-
tion of AI.
Short-term changes in Ki67 are not intended to be
used for treatment decisions in individual patients. How-
ever, they do support the use of this clinical model for
the evaluation of new agents before the initiation of
large-scale adjuvant trials. Independently of ER-α status,
the results from our prospective study demonstrate that
ER-β- positive BC treated with anastrozole and tamoxi-
fen presents a significant reduction in Ki67 expression
after neoadjuvant short-term treatment compared with
placebo and ER-β-negative cases. In a 58 ER-α-positive
BC patient study, Mattar et al [28] demonstrated that
short-term tamoxifen therapy was not associated with a
significant reduction in Ki67 expression. However, some
important studies have demonstrated paradoxical Ki67
increases after neoadjuvant endocrine therapy [23,24,39].
Ellis et al [24] observed an increase in Ki67 with treat-
ment in HER1/2-negative cases. The molecular basis
for this advantage appears complex but includes a pos-
sible tamoxifen agonist effect in ER-α-positive BC. In
addition, the degree of Ki67 suppression varies markedly
between tumors in some trials [25], and this indicates
that the degree of estrogenic dependence is highly vari-
able between tumors.
Our data indicate that ER-β positivity could predict
the tamoxifen effect in BC treatment with no initial
increase of Ki67 (the tamoxifen flare phenomenon). In
fact, there is substantial evidence for ER-β as a predictor
of the tamoxifen endocrine response [17,40,41]. Re-
cently, Yan et al [42] analyzed ER-β and its co-regulator
Steroid Receptor RNA Activator Protein (SRAP) expres-
sion in tissue microarrays from a randomized, placebo-
controlled trial and found that the benefit was only in
the tamoxifen-treated but not in the placebo arm; there-
fore providing evidence that ER-β expression was
Figure 4 Pretreatment Allred scores ratios of ER-α/ER-β and post-treatment Ki67 expression. Immunohistochemical staining showing
different examples of ER-α/ER-β ratios: Case 2 (ratio < 1) with a poor variation in Ki67 level; Case 37 (ratio between 1 and 1.5) with a significant
difference in Ki67 level after treatment and Case 28 (ratio > 1.5) with no significant change in Ki67 expression.
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mor growth and survival particularly in ER-α-negative
premenopausal early BC. Another study indicated that
ER-β enhances the antiestrogenic actions of endoxifen
in BC cells [43]. Thus, the potential benefit from
tamoxifen therapy observed in our clinical study withKi
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Figure 5 Ki67 Biomarker in patients with an ER-α/ER-β score
ratio between 1 and 1.5.patients whose tumors are ER-β-positive may be medi-
ated through the actions of endoxifen. In addition, the
ability of low endoxifen concentrations to significantly
inhibit estrogen-induced gene expression and prolifera-
tion in ER-β-expressing BC cells suggests that the bene-
fits from tamoxifen therapy may still be observed in
patients characterized as poor metabolizers based on
their Cytochrome P450 2D6 genotype if their tumors are
ER-β-positive [43]. Tamoxifen is an effective drug, but 2
drawbacks are associated with its clinical use: not all ER-
α-positive BCs respond to tamoxifen, and most patients
develop resistance to tamoxifen with prolonged use.
Given recent insights into the understanding of estrogen
signaling and how ER-β is involved, these negative as-
pects of tamoxifen can be understood, and better
methods for testing cancers for sensitivity to tamoxifen
and for the development of tamoxifen resistance are
available [44]. The assessment of pretreatment ER-β
phenotype and changes in that phenotype with therapy
alongside the changes in Ki67, as observed in our data,
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the variable response observed and lead to strategies that
may overcome tamoxifen resistance.
The most important question for clinicians is whether
the ER-β status provides clinically useful information
over what is already provided by the traditional ER-α
/PgR assay. On this matter, there are 2 groups of BCs,
one in which ER-β is coexpressed with ER-α and the
other in which ER-β is expressed alone. The first group
comprises approximately 59% of all primary BCs, while
the ER-β alone-expressing group comprises approxi-
mately 17% [34]. Promising findings in ER-β-positive/
ER-α-negative BC cases have demonstrated that ER-β
status is a significant prognostic factor in univariate and
multivariate analysis [17]. In this study based on the
archival material of 442 BCs from women treated with
adjuvant tamoxifen, ER-β positivity in ER-α/PgR-nega-
tives cases was associated with significantly better sur-
vival compared with ER-β negative BC. In ER-α-negative
tumors, ER-β expression appears to be associated with
longer disease-free survival upon endocrine treatment
[41]. Some findings also indicate the possibility that ER-β
expression levels might be especially relevant for prognos-
tic stratification of the ER-α-positive/PgR-positive tumors,
which have a more favorable natural history [45].
Shortly after the discovery of ER-β, it was shown that
ER-β mediates other and opposite effects to those of ER-
α [46]. Upon ligand activation, the receptors dissociate,
change conformation and form functional dimers at spe-
cific DNA elements. Depending on the presence of ER-α
and ER-β in a certain cell, the receptors form functional
homo- or heterodimers on promoter elements [40]. ER-
β appears to reduce the cell proliferation induced by ER-
α activation. Since the first evidence that ER-β is an
important modulator of proliferation and invasion of BC
cells, it has been shown that the ratio of ER-α/ER-β ex-
pression is higher in BC than normal tissues due to the
lower expression of ER-β, supporting the hypothesis first
shown by League et al [47] that the loss of ER-β expres-
sion could be one of the events leading to the develop-
ment of BC tumorigenesis. The reason for this loss of
ER-β in cancer appears to be the silencing of ER-β via
promoter methylation [44,48].
The identification of five major variants of ER-β (β1,
β2/cx, β3, β4 and β5), mainly generated through alterna-
tive splicing events, increases the complexity of interpreting
the literature data accumulated using only one antibody for
immunodetection of ER-β expression [49,50]. There is no
consensus regarding the function of each variant and
contradictory results concerning potential function have
been published [51]. It seems that the variant ER-β
isoforms can modify both ER-α and ER-β1 activity when
co-expressed. Therefore, differential expression of the ER-β
variants may play a role in the so-called bi-faceted ER-βaction and sensitivity to antiestrogens during breast
tumorigenesis and breast cancer progression [49]. Our
immunostainings were carried out using a monoclonal
anti-ER-β antibody (clone 14C8 from GeneTex), which is
pan-specific for ER-β isoforms. Therefore, we evaluated
total ER-β protein levels by performing immunohisto-
chemistry using this well-characterized antibody, previ-
ously shown to be one of the best-performing antibodies
for this application [52].
Our data also indicate a weak but positive correla-
tion between ER-α and ER-β and demonstrate signifi-
cant decreases in Ki67 levels after treatment with both
anastrozole and tamoxifen only in patients with a ratio
of ER-α/ER-β Allred scores between 1 and 1.5. No
changes in Ki67 levels were observed in patients with
higher ER-β than ER-α scores (ratio < 1) or with much
higher ER-α scores than ER-β (ratio > 1.5). The effects of
hormonal treatment on cell proliferation are apparently
dependent on the actual ratio of ER-α/ER-β expression
levels in these tumors and not only the receptor positiv-
ity. Sotoca et al [53] investigated how variable cellular
expression ratios of ER-α and ER-β modulate the effects
on cell proliferation induced by ER-α or ER-β agonists,
respectively. Consistent with our results, they found the
use of ER-β protein expression levels as a biomarker in
tumor screening, in addition to protein expression levels
of ER-α, to be a more successful indication of thera-
peutic responses and course/outcome of the disease in
ER-positive tumors [53]. In fact, in vitro studies have in-
dicated that a tamoxifen treatment of ER-α BC cells has
an even stronger effect in the presence of ER-β [12]. Be-
cause ER-α and ER-β differ in affinity for promoter ele-
ments, this might explain their difference in tamoxifen
responses. Estrogen response element activity is re-
pressed by both ER-α and ER-β in the presence of
tamoxifen, while activator protein 1 (AP-1) responsive
elements are activated by both receptors in the presence
of tamoxifen. When ER-β is expressed in parallel with
ER-α, which is the case of our patients with a ratio of
ER-α/ER-β Allred scores between 1 and 1.5, the activa-
tion of AP-1 elements is inhibited by ER-β [40,54], and
this could play an important role in the behavior of BC
cells in response to tamoxifen. The role of ER-β in re-
sponse to AI therapy is unclear. In a study by Torrisi et al
[38], it was found that ER-β is significantly up-regulated,
whereas ER-α is down-regulated after treatment of 32
premenopausal women with BCs with adjuvant letrozole
in combination with a GnRH analogue. Our study with
postmenopausal women treated with anastrozole also
demonstrated a decrease in Ki67 levels after treatment
with anastrozole only in patients with a ratio of ER-α/ER-
β Allred scores between 1 and 1.5. It is possible that ER-β
or its relationship with ER-α is important in the thera-
peutic response to AI.
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[35] who have suggested that the assessment of ER-β to-
gether with ER-α is a better predictor of endocrine re-
sponsiveness than ER-α alone. In addition, as some
studies have suggested that ER-β correlates with and
regulates PgR expression together with ER-α [55-57], it
is possible that ER-β and ER-α could be better bio-
markers than ER-α and PgR. It is also possible that the
3 receptors in combination may provide the most pre-
cise prediction of endocrine responsiveness.
Our study was hampered by relatively small sample
size. The number of cases according to positive or nega-
tive hormone receptors (especially for the ER-β-negative
and ER-α-negative cases) prevented a separate statistical
analysis of Ki67 changes after treatment in each group.
A systematic and larger study, taking ER-β status into
consideration, for patients with different positivity for
receptors (ER-β, ER-α and PgR) could better characterize
each cancer and help to optimize adjuvant treatment for
BC patients. Some differences of our conclusions com-
pared with other studies should be drawn keeping in
mind the large amount of ER-β antibodies used in the
literature and the various cut points for determining
the positivity of ER-α and ER-β. Some published data
on the usefulness of several ER-β antibodies for a num-
ber of analyses including immunohistochemistry have
underscored the marked variations in specificity and
likely sensitivity that exist for the different antibodies
currently available [58]. In addition, our Brazilian popu-
lation is one of the most heterogeneous in the world,
formed mainly by the admixture between European,
African and Native American populations and, more
recently, individuals of Asian origins. These race-
specific factors may also influence our findings com-
pared with the white population of others studies. Al-
though no studies have examined specifically differences
in ER-β protein expression with regards to ethnicity, two
studies showed that ER-β mRNA levels are significantly
decreased in ER-α-positive BC from African American
women [59] and from East Asian women [60]. It should
also be noted that the patients enrolled onto this trial
represent only a small percentage of our whole postmen-
opausal BC population treated in our institutions during
the entry period. Several studies failed to find significant
correlations between ER-β expression and patient age
[11], however, it may be considered another limitation of
our study.
Conclusions
Our results demonstrated for the first time for neoadjuvant
short-term treatment that ER-β expression did not change
during endocrine treatment and may predict the effects of
anastrozole and tamoxifen in postmenopausal BC patients.
These effects of hormonal treatment on cell proliferationappear to be dependent on the ratio of ER-α/ER-β expres-
sion. This study supports further investigation into whether
ER-β could be a predictor of endocrine responsiveness or
whether the receptor could be used as a target in selected
groups of BC.
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